LOTEPREDNOL ETABONATE 0.5%w/v IP + TOBRAMYCIN SULPHATE 0.3%w/v IP + BENZALKONIUM...

A topical ophthalmic combination [corticosteroid/antibiotic] for the management of various ocular surface inflammatory conditions with, or at risk for, a bacterial infection. (James E Deom, 2022) An effective ophthalmic suspension for the treatment of ocular inflammation associated with blepharokeratoconjunctivitis. (Eric M White, 2008) A viable combination therapy that increases convenience that promotes patient adherence. (Karpecki, 2021) Demonstrates high rates of bacterial eradication in patients with bacterial conjunctivitis (94.3–98.5%) and blepharoconjunctivitis (88.9%). (Karpecki, 2021) A well-tolerated agent in pediatric populations 0 to 6 years of age with blepharitis or blepharoconjunctivitis. (Karpecki, 2021) A safer therapeutic option for ocular inflammation that carries a risk of superficial bacterial infections. (Timothy L Comstock E. J., 2010) Protects against infection after surgery as well as treats existing infections by eradicating susceptible organisms. (Karpecki, 2021) An efficacious drug in a range of inflammatory ocular conditions along with a safety profile including a low risk of intraocular pressure elevation. (James E Deom, 2022) Provides coverage against a broad spectrum of common ocular pathogens. (James E Deom, 2022) A suitable treatment option for blepharitis, including that caused by a staphylococcal infection. (Karpecki, 2021) An appropriate treatment for other ocular surface inflammatory conditions that carry a risk of infection, such as contact lens-induced red eye. (Karpecki, 2021) A potent therapeutic option that is effective in reducing the signs of blepharitis. (Timothy L Comstock, 2017) Demonstrates a favorable safety profile than dexamethasone 0.1%/tobramycin 0.3% ophthalmic suspensions in blepharitis subjects. (Timothy L Comstock, 2017)